Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Ontology highlight
ABSTRACT: OBJECTIVES:Stage I, grade 1 endometrial cancers have low recurrence rates and often do not receive adjuvant therapy. We compared recurrent cases to matched non-recurrent controls to evaluate for molecular markers associated with higher risk of recurrence. METHODS:A case-control study including all cases of recurrent stage I, grade 1 endometrioid endometrial cancer at one institution in a ten-year period. Cases were matched to controls by age, BMI, weight and stage. Molecular testing and immunohistochemistry were performed on archival tumor specimens: microsatellite instability (MSI-H), mismatch repair status, POLE mutational status, and next-generation sequencing. RESULTS:15 stage I, grade 1 endometrial cancer cases with recurrent disease and available tumor specimens were identified. CTNNB1 and MSI-H were present at significantly higher rates in cases than controls (CTNNB1 60% vs. 28%, OR 3.9, 95%CI 1.1-14.7, p?=?0.04 and MSI-H 53% vs. 21%, OR 4.4, 95%CI 1.1-17.0, p?=?0.03). POLE mutations were found in 0% of cases vs. 7% of controls (p?=?0.54). Among specimens demonstrating microsatellite stability (MSS), 100% of cases vs. 26% of controls had CTNNB1 mutations (p?
SUBMITTER: Moroney MR
PROVIDER: S-EPMC7005911 | biostudies-literature | 2019 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA